knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 23:48:15 - browse：98315

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： European regulators recommend Amylyx's ALS drug be rejected

hotspot

WSS

Humana CEO Bruce Broussard to step down in 2024

IRA could hurt research into orphan drugs for rare diseases

Hospitals consider fixing cancer drug shortages on their own

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

European regulators recommend Amylyx's ALS drug be rejected

European regulators consider appeal over Amylyx ALS drug

Wikipedia

knowledge

hotspot

New air purifier tech could be key to improving indoor air quality

FDA panel endorses Alnylam’s heart drug — after picking it apart

Walensky prepares to leave CDC — and Congress — behind

New weight loss drugs vying to be the next Wegovy or Mounjaro

In age of alternative facts, a scholarly course on calling out crap

WATCH: Why do bright lights make us see spots?

Anesthesiologist group: stop taking Ozempic before surgery

Private equity could exacerbate cardiology's overuse problem, experts fear

Guidelines to prevent youth baseball injuries need more muscle

Acelyrin, a rare IPO success, stumbles in its first big test

focus

Walmart eyes Medicare Advantage provider ChenMed

Food makers to regulators: Ultra

A revolution in caring for preterm infants

A common UTI test for kids haunts adults as a traumatic 'nightmare'

Life sciences deals on track to hit lowest point since 2017

Will the IRA bring competition to the biologics market?

knowledge

entertainment

hotspot

leisure time